LUSSO, PAOLO
 Distribuzione geografica
Continente #
EU - Europa 15.278
NA - Nord America 3.786
AS - Asia 423
AF - Africa 4
OC - Oceania 4
SA - Sud America 2
Totale 19.497
Nazione #
IT - Italia 14.448
US - Stati Uniti d'America 3.782
UA - Ucraina 349
CN - Cina 294
SE - Svezia 220
SG - Singapore 84
FI - Finlandia 80
GB - Regno Unito 74
DE - Germania 60
IN - India 38
FR - Francia 27
RU - Federazione Russa 16
TR - Turchia 5
AU - Australia 3
CA - Canada 3
MU - Mauritius 3
NL - Olanda 2
BR - Brasile 1
CL - Cile 1
ES - Italia 1
HK - Hong Kong 1
IE - Irlanda 1
KR - Corea 1
MX - Messico 1
NZ - Nuova Zelanda 1
ZA - Sudafrica 1
Totale 19.497
Città #
Cagliari 14.134
Woodbridge 536
Fairfield 534
Houston 342
Chandler 315
Ashburn 254
Seattle 239
Ann Arbor 224
Cambridge 203
Wilmington 196
Boardman 193
Jacksonville 189
Nyköping 153
Uta 143
Santa Clara 57
Boston 55
Nanjing 50
San Diego 43
Singapore 38
Beijing 35
Shanghai 32
Milan 31
Verona 29
Pune 27
Helsinki 24
Hebei 22
Nanchang 22
Jiaxing 20
Los Angeles 20
Changsha 17
Shenyang 16
Jinan 15
Tianjin 15
Sassari 14
Guangzhou 9
Norwalk 8
London 7
Zhengzhou 7
Mountain View 6
Ningbo 6
Orange 6
Saint Petersburg 5
Redwood City 4
Taizhou 4
Washington 4
Bangalore 3
Dearborn 3
Delhi 3
Kunming 3
New York 3
Paris 3
Tonara 3
Toronto 3
Atlanta 2
Castellammare di Stabia 2
Cedar Knolls 2
Chicago 2
Frankfurt am Main 2
Gallatin 2
Hangzhou 2
Hefei 2
Hounslow 2
Kilburn 2
Legnano 2
Melzo 2
Rome 2
San Jose 2
Walnut 2
Auckland 1
Chiswick 1
Chongqing 1
Ciudad Nezahualcoyotl 1
Dalian 1
Denver 1
Dublin 1
Erlangen 1
Geislingen an der Steige 1
Hamburg 1
Hong Kong 1
Lanzhou 1
Leawood 1
Melbourne 1
Miami 1
Millbury 1
Neu-Ulm 1
New Delhi 1
Novokuznetsk 1
Perugia 1
Prescot 1
Qingdao 1
Redmond 1
San Mateo 1
Santiago 1
Silver Spring 1
Southwark 1
São Paulo 1
Wandsworth 1
Wuhan 1
Totale 18.387
Nome #
Infection with hepatitis C virus depends on TACSTD2, a regulator of claudin-1 and occludin highly downregulated in hepatocellular carcinoma 1.573
Calibration Technologies for Correct Determination of Epstein-Barr Virus, Human Herpesvirus 6 (HHV-6), and HHV-8 Antiviral Drug Susceptibilities by Use of Real-Time-PCR-Based Assays 542
Chromosomally integrated human herpesvirus 6: questions and answers 526
Tyrosine sulfation in the second variable loop (V2) of HIV-1 gp120 stabilizes V2-V3 interaction and modulates neutralization sensitivity 517
Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor 515
Glycosylation, Hypogammaglobulinemia, and Resistance to Viral Infections 513
Enhancement of Anti-HIV-1 Activity by Hot Spot Evolution of RANTES-Derived Peptides 507
Development of a Human Herpesvirus 6 Species-Specific Immunoblotting Assay 491
Classification of HHV-6A and HHV-6B as distinct viruses 487
Selective Reactivation of Human Herpesvirus 6 in Patients With Autoimmune Connective Tissue Diseases 486
A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses 471
Calibrated real-time polymerase chain reaction for specific quantitation of HHV-6A and HHV-6B in clinical samples 457
Treatment with IL-7 Prevents the Decline of Circulating CD4(+) T Cells during the Acute Phase of SIV Infection in Rhesus Macaques 453
The CD8-Derived Chemokine XCL1/Lymphotactin Is a Conformation-Dependent, Broad-Spectrum Inhibitor of HIV-1 452
HHV-6 encephalitis in umbilical cord blood transplantation: a systematic review and meta-analysis 429
Sialic acid-binding Ig-like lectin-7 interacts with HIV-1 gp120 and facilitates infection of CD4(pos) T cells and macrophages 427
lmmunomodulation and immunosuppression by human herpesvirus 6A and 6B 426
Protein-based HIV-1 microbicides. 423
Molecular study of human herpesvirus 6 and 8 involvement in coronary atherosclerosis and coronary instability 423
IL-7 induces expression and activation of integrin alpha 4 beta 7 promoting naive T-cell homing to the intestinal mucosa 371
Inhibition of HIV-1 Infection by Human alpha-Defensin-5, a Natural Antimicrobial Peptide Expressed in the Genital and Intestinal Mucosae 370
Human herpesvirus 6A accelerates AIDS progression in macaques 316
The superior folding of a RANTES analogue expressed in lactobacilli as compared to mammalian cells reveals a promising system to screen new RANTES mutants 311
The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT 310
Evolution of SIV toward RANTES resistance in macaques rapidly progressing to AIDS upon coinfection with HHV-6A 307
Biological and physical characterization of the X4 HIV-1 suppressive factor secreted by LPS-stimulated human macrophages 296
Reactivation of human herpesvirus 6 (HHV-6) infection in patients with connective tissue diseases 290
Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers 285
A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load 284
A multiplex calibrated real-time PCR assay for quantitation of DNA of EBV-1 and 2 284
Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection 283
Broad-Spectrum Inhibition of HIV-1 by a Monoclonal Antibody Directed against a gp120-Induced Epitope of CD4 278
Combinatorial optimization of a CD4-mimetic miniprotein and cocrystal structures with HIV-1 gp120 envelope glycoprotein 277
International network for comparison of HIV neutralization assays: the NeutNet report 274
Clinical significance of HIV-1 coreceptor usage 273
Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity 270
Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer 267
Rational design of novel HIV-1 entry inhibitors by RANTES engineering 264
HHV-6 and CMV pneumonitis in immunocompromised patients 237
Identification of RANTES MIP-1 alpha and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells 237
Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains 233
Selective suppression of IL-12 production by human herpesvirus 6 223
Interleukin 7 reduces the levels of spontaneous apoptosis in CD4+ and CD8+ T cells from HIV-1-infected individuals 221
Nef-specific CD45RA+ CD8+ T cells secreting MIP-1beta but not IFN-gamma are associated with nonprogressive HIV-1 infection 220
HHV-6 and the immune system: mechanisms of immunomodulation and viral escape 216
A relapsing inflammatory syndrome and active human herpesvirus 8 infection 214
Infection of natural killer cells by human herpesvirus 6 210
: Alpha-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4 208
CD46 is a cellular receptor for human herpesvirus 6 195
HIV and the chemokine system 192
Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation 191
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression 188
Suppression of CCR5- but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6 184
A rationally designed CD4 mimic inhibits HIV-1 entry and exposes cryptic neutralization epitopes 166
Structural determinants of HIV-1 blockade and CCR5 recognition in RANTES 163
Critical role of the N-loop and beta1-strand hydrophobic clusters of RANTES-derived peptides in anti-HIV activity 160
HIV and chemokines: Implications for therapy and vaccines 157
Totale 19.543
Categoria #
all - tutte 36.611
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.611


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.495 0 0 0 0 2.528 1.561 765 253 138 47 74 129
2020/20215.660 213 161 104 2.139 1.687 466 312 213 47 126 122 70
2021/2022652 49 121 39 19 36 15 44 29 64 42 94 100
2022/20231.191 130 115 112 97 101 175 46 127 126 37 55 70
2023/20241.601 120 47 72 172 143 143 86 110 82 329 131 166
2024/2025690 101 101 243 93 152 0 0 0 0 0 0 0
Totale 19.543